WE PERCEIVE. WE PREPARE. WE PROTECT.

Emergent BioSolutions Appoints Industry Leader Joseph C. Papa as New President and CEO

We’re pleased to announce that Joseph C. Papa is Emergent’s new president and chief executive officer, beginning a new era of empowering communities, protecting public health, and returning to growth.

Continuing 25 years of protecting against public health threats

Whether it’s increasing access to NARCAN® Nasal Spray, which is helping combat the opioid epidemic, or continuing to deliver vaccines and therapeutics, Emergent’s focus remains on protecting communities and addressing the evolving landscape of global health challenges.

LEARN MORE

Joseph C. Papa

Capabilities

We are a leader in providing solutions that address public health threats and bring lifesaving, life-extending products to market.

  • Commercial Products

    We offer commercialized products that address endemic public health threats such as the opioid epidemic.

  • Medical Countermeasures

    Emergent specializes in developing, manufacturing, and stockpiling medical countermeasures for military and civilian populations that target some of the deadliest public health threats.

  • Bioservices

    Emergent offers molecule-to-market drug substance and drug product development and manufacturing services to biopharma innovators, government, and non-government organizations.

Woman in Lab

At Emergent, our mission is to protect and enhance life.

Our Impact

Emergent BioSolutions Reports Fourth Quarter 2023 Financial Results

GAITHERSBURG, Md., March 06, 2024 -- Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the quarter and year ended December 31, 2023.

Emergent BioSolutions to Release Fourth Quarter & Full Year 2023 Financial Results, and Conduct Conference Call on March 6, 2024

GAITHERSBURG, Md., Feb. 29, 2024 -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Wednesday, March 6, 2024, at 5:00 pm eastern time to discuss the financial results for the fourth quarter and full year 2023. Emergent’s newly appointed president and CEO, Joseph C. Papa, will provide remarks.

Emergent BioSolutions Appoints Industry Leader Joseph C. Papa as New President and CEO

GAITHERSBURG, Md., Feb. 21, 2024 -- Emergent BioSolutions Inc. (NYSE: EBS), a global company providing solutions that address public health threats and delivering life-extending products to market, today announced that its Board of Directors has appointed Joseph C. Papa as president and CEO, effective February 21, 2024.

This website uses cookies. This site uses cookies to provide you with a more responsive and personalized service. By using this site you agree to the Privacy Notice and Terms of Use.